NCT06811324View on ClinicalTrials.gov

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2026

Conditions
Obesity PreventionSarcopenia in ElderlyCardiovascular FunctionGLP - 1Weight Loss
Interventions
DRUG

Tirzepatide

Once weekly tirzepatide starting at 2.5 mg/weekly, with dose escalation monthly by 2.5 mg to a target dose of 10 mg/weekly or maximum tolerated

Trial Locations (1)

78229

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER